- PROFESSOR Medicine, General Internal Medicine
MD, University of Buenos Aires, Argentina
MPH, Columbia University
DrPH, Columbia University
- Dr. Wisnivesky is a pulmonologist and clinical epidemiologist whose research focuses on asthma, cancer epidemiology and outcomes research. He is the Vice Chairman for Research of the Department of Medicine and the Associate Division Chief of the Division of General Internal Medicine. Dr. Wisnivesky has been the Principal Investigator (PI) of three R01s to conduct secondary data analysis using the Surveillance, Epidemiology and End Results (SEER)-Medicare registry to evaluate the diagnosis, staging, and treatment of lung cancer. He is also the PI of an American Cancer Society funded cohort study assessing the determinants of disparities in the diagnosis and treatment of lung cancer. Dr. Wisnivesky has considerable experience using the SEER registry and the SEER-Medicare database. He has published several manuscripts using these databases addressing issues related to the diagnosis, treatment, disparities in care, and outcomes of patients with lung cancer.
He received a K award from the Agency for Healthcare Research and Quality (AHRQ) to identify determinants of medication adherence and outcomes among inner-city asthmatics and a grant funded by the New York State Department of Health to assess the management of minority asthmatics. He has also been involved in several inpatient, outpatient and physician studies assessing the treatment and outcomes of inner-city asthmatics. He is also the PI of an R01 grant evaluating self-management of patients with chronic obstructive pulmonary disease. He was the PI of an R03 grant to validate a pulmonary tuberculosis prediction rule.
Mount Sinai Study Shows that Language Barriers may Interfere with the Care of Asthma Patients.
Find out more here
Dr. Juan Wisnivesky discusses lung cancer risks in The Daily News feature The Daily Check Up.
Research Excellence Award
Department of Medicine, MSSM
Joseph L. Fleiss Prize Biostatistics , Columbia University
Young Investigator Award
J. Burns Amberson Fellow
American Lung Association of New York
Outstanding House Officer Award
Montefiore Medical Center, Albert Einstein College of Medicine
University of Buenos Aires School of Medicine
Research interests include:Asthma, lung cancer screening, Tuberculosis
Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women?. J Clin Oncol 2007; 25(13): 1705-1712.
Wisnivesky JP, Henschke C, Yankelevitz D. Diagnostic percutaneous transthoracic needle biopsy does not affect survival of stage I lung cancer. Am J Respir Crit Care Med 2006; 174(6): 684-688.
Wisnivesky JP, McGinn T, Henschke C, Hebert P, Iannuzzi M, Halm E. Ethnic disparities in the treatment of stage I non-small cell lung cancer. Am J Respir Crit Care Med 2005; 171: 1158-1163.
Wisnivesky JP, Kaplan J, McGinn T, Henscke C, Crystal RG. Evaluation of clinical parameters to predict positive culture for Mycobacterium Tuberculosis in inpatients. Arch Int Med 2000; 160: 2471-2476.
Wisnivesky JP, Kattan M, Evans D, Leventhal H, Musumeci-Szabó TJ, McGinn T, Halm EA. Assessing the relationship between language proficiency and asthma morbidity among inner-city asthmatics. Medical care 2009 Feb; 47(2).
Wisnivesky JP, Henschke CI, Swanson S, Yankelevitz DF, Zulueta J, Marcus S, Halm EA. Limited resection for the treatment of patients with stage IA lung cancer. Annals of surgery 2010 Mar; 251(3).
Wisnivesky JP, Halm E, Bonomi M, Powell C, Bagiella E. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. American journal of respiratory and critical care medicine 2010 Feb; 181(3).
Wisnivesky JP, Arciniega J, Mhango G, Mandeli J, Halm EA. Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer. Thorax 2011 Apr; 66(4).
Wisnivesky JP, Smith CB, Packer S, Strauss GM, Lurslurchachai L, Federman A, Halm EA. Effectiveness and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Resected Stage II and IIIA Lung Cancer: Observational Cohort Analysis. BMJ 2011; 343.
Wisnivesky JP, Teitelbaum S, Todd AC, Boffetta P, Crane M, Crowley L, de la Hoz R, Dellenbaugh C, Harrison D, Herbert R, Kim H, Jeon Y, Kaplan J, Katz C, Levin S, Luft B, Markowitz B, Moline JM, Ozbay F, Pietrzak RH, Shapiro M, Sharma V, Skloot G, Southwick S, Stevenson LA, Udasin I, Wallensteiin S, Landrigan PJ. Persistence of multiple illnesses in World Trade Center rescue and recovery workers: a cohort study. Lancet 2011 September; 378: 888-97.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Wisnivesky during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Bristol-Myers Squibb; IMS Health Incorporated; Merck & Co., Inc.; Quintiles
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
17 East 102 Street Floor 6th Floor West Tower
New York, NY 10029